ArticleCureus2026
Abdominal Wall Erythema as a Suspected Extracardiac Manifestation of Cardiac Allograft Rejection.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a heart transplant recipient, a new cutaneous finding can be difficult to attribute to a single cause, and the clinical context does not always point to localized skin disease. We describe the case of a 54-year-old man five years after orthotopic heart transplantation who presented with severe periumbilical pain, hypoxemia, and abdominal wall erythema one week after completing intravenous immunoglobulin and rituximab for biopsy-proven antibody-mediated rejection (AMR). Computed tomography suggested paraumbilical cellulitis and possible pulmonary infection, and empiric antibiotics were appropriately initiated. However, the erythema was non-purulent and non-necrotizing, blood cultures were negative, there was no clear bacterial skin source, the patient's atypical pretransplant ischemic pain phenotype had recurred, and the tacrolimus trough was subtherapeutic at 3.4 ng/mL, together raising concern for ongoing allograft immune injury. This case supports treating apparent cellulitis while urgently considering an extracardiac manifestation of graft rejection when support for a localized infectious source is weak and the transplant context is high risk. Preserved left ventricular ejection fraction does not exclude recurrent AMR or cardiac allograft vasculopathy, and early transplant-center coordination remains the critical management step.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.